Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma

Inclusion Criteria:

* Written informed consent prior to study specific screening procedures;
* Favorable index of curative effect of Diffuse Large B Cell Lymphoma confirmed by histological analysis;
* ≥ 18 and ≤ 70 years of age, male or female;
* Advanced Lymphoma and standard treatments failed;
* May benefit from anthracycline-based drugs;
* ECOG performance status of 0-2;
* More than 4 weeks from the last chemotherapy, more than 4 weeks from the last biotherapy, more than 4 weeks from the last clinical trial drug therapy;
* Life expectancy of more than 3 months;
* Sexually active women of childbearing potential must use a medically acceptable form of contraception;
* Adequate hepatic, renal, cardiac and hematologic functions: leukocyte≥3.5×10\^9/L,neutrophils≥2.0×10\^9/L,platelets≥100×10\^9/L, hemoglobin≥90g/L,creatinine clearance rate≤1.5×ULN, serum bilirubin≤1.5×ULN, ALT≤2.5×ULN(5×for liver metastasis),AST≤2.5×ULN(5×for liver metastasis), alkaline phosphatase≤200 IU/L,Electrocardiogram appeared to be essentially normal, ejection fraction of Heart Doppler ultrasound appeared to be normal.

Exclusion Criteria:

* Pregnant or lactating women;
* Patients with Multiple sclerosis;
* Suffering from serious internal disease, including serious heart attack, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension,uncontrolled infection, Active peptic ulcer;
* Mitoxantrone has been used before;
* The cumulative does of doxorubicin and epirubicin before inclusion have surpassed 360 mg/m2 and 600 mg/m2, respectively;
* Heart disease was caused after Anthracycline-based drugs used;
* Other antineoplastic drugs need to be used in this study;
* History of Anthracycline-based drug allergy or liposome drug allergy;
* Uncontrolled primary brain tumor or brain metastases;